A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

This study is currently recruiting participants. (see Contacts and Locations)
Verified January 2014 by Therapeutic Advances in Childhood Leukemia Consortium
Sponsor:
Information provided by (Responsible Party):
Therapeutic Advances in Childhood Leukemia Consortium
ClinicalTrials.gov Identifier:
NCT01483690
First received: November 29, 2011
Last updated: January 31, 2014
Last verified: January 2014

November 29, 2011
January 31, 2014
December 2011
June 2014   (final data collection date for primary outcome measure)
Number of participants with adverse events. [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]
To evaluate the side effects of giving decitabine and vorinostat before and during chemotherapy using the standard drugs vincristine, dexamethasone, PEG-asparaginase and mitoxantrone.
Same as current
Complete list of historical versions of study NCT01483690 on ClinicalTrials.gov Archive Site
  • Disease response rate after treatment. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    The study will assess whether the patient's acute lymphoblastic leukemia goes into remission after treatment.
  • Gene-specific methylation profiles [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess the biologic activity of decitabine by comparing pre and post-treatment marrow samples for global and gene-specific methylation profiles using HELP and methylation-specific PCR.
  • Global histone acetylation and histone modifications [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess the biological activity of vorinostat by comparing pre- and post-treatment blood and bone marrow samples for global histone acetylation (using acetyl-H3 Western blotting), and for gene-specific histone modifications (using H3K9/14Ac ChIP-chip and ChIP-qPCR).
  • Gene expression profiles [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the impact of combined epigenetic therapy on the expression of epigenetically-regulated genes by comparing pre and post-treatment marrow samples for gene expression profiles (using microarrays), and correlating these with the methylation and histone modification assays.
  • Disease response rate after treatment. [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
    The study will assess whether the patient's acute lymphoblastic leukemia goes into remission after treatment.
  • Gene-specific methylation profiles [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess the biologic activity of decitabine by comparing pre and post-treatment marrow samples for global and gene-specific methylation profiles using HELP and methylation-specific PCR.
  • Global histone acetylation and histone modifications [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To assess the biological activity of vorinostat by comparing pre- and post-treatment blodd and bone marrow samples for global histone acetylation (using acetyl-H3 Western blotting), and for gene-specific histone modifications (using H3K9/14Ac ChIP-chip and ChIP-qPCR).
  • Gene expression profiles [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    To determine the impact of combined epigenetic therapy on the expression of epigenetically-regulated genes by comparing pre and post-treatment marrow samples for gene expression profiles (using microarrays), and correlating these with the methylation and histone modification assays.
Not Provided
Not Provided
 
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL

This is a pilot study using decitabine and vorinostat before and during chemotherapy with vincristine, dexamethasone, mitoxantrone, and peg-asparaginase in pediatric patients with acute lymphoblastic leukemia (ALL).

Decitabine is a demethylating agent and vorinostat is a HDAC inhibitor. The use of demethylating agents and HDAC inhibitors in combination have been previously shown to have synergistic effects in altering neoplastic pathways of cancer cells and be well tolerated in human clinical studies. With the ability of decitabine and vorinostat to alter the abnormal cellular pathways of leukemic blasts and essentially turn off anti-apoptotic proteins, the leukemia cells have become primed for cytotoxic cell kill via chemotherapeutic agents. This study will ask the question as to whether or not the combination of decitabine and vorinostat followed by chemotherapy is feasible and whether it can positively impact outcome in patients with relapsed or refractory acute lymphoblastic leukemia.

Interventional
Phase 1
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Acute Lymphoblastic Leukemia
  • Precursor B-Cell Lymphoblastic Leukemia
  • Precursor T-Cell Lymphoblastic Leukemia
  • Drug: Decitabine
    10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
    Other Name: Dacogen
  • Drug: Vorinostat
    180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
    Other Names:
    • Zolinza
    • suberoylanilide hydroxamic acid (SAHA)
  • Drug: Vincristine
    1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
    Other Names:
    • Oncovin
    • Vincasar PFS
    • Vincrex
    • vincristine sulfate
    • VCR
  • Drug: Dexamethasone
    20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
    Other Names:
    • Decadron
    • Dexamethasone Intensol
    • dexamethasone acetate
    • dexamethasone sodium phosphate
  • Drug: Mitoxantrone
    10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
    Other Names:
    • Novantrone
    • DHAD
    • DHAQ
  • Drug: Pegaspargase
    2500 international units/m2/day IM or IV on days 10 and 24.
    Other Names:
    • Oncospar
    • PEG-L-asparaginase
  • Drug: Methotrexate

    Given intrathecally to all patients the dose defined by age below.

    • 8 mg for patients age 1-1.99
    • 10 mg for patients age 2-2.99
    • 12 mg for patients 3-8.99 years of age
    • 15 mg for patients >9 years of age

    CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35

    Other Names:
    • Folex
    • Mexate
    • MTX
    • Methotrex
Not Provided
Raetz EA, Bhatla T. Where do we stand in the treatment of relapsed acute lymphoblastic leukemia? Hematology Am Soc Hematol Educ Program. 2012;2012:129-36. doi: 10.1182/asheducation-2012.1.129.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
16
Not Provided
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients must be ≥1 and ≤ 21 years of age when originally diagnosed with ALL.

Diagnosis

  • Patients must have a diagnosis of acute lymphoblastic leukemia (ALL) with ≥ 25% blasts in the bone marrow (M3), with or without extramedullary disease.
  • Patients may have CNS 1, 2 or 3 disease.
  • Karnofsky > 50% for patients > 16 years of age and Lansky > 50% for patients ≤ 16 years of age.
  • Prior Therapy
  • Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • Patients must have had 2 or more prior therapeutic attempts defined as:
  • Relapse after going into remission from re-induction for the first or subsequent relapse (ie: 2nd , 3rd, 4th…relapse), OR
  • Refractory disease after first or greater relapse and a re-induction attempt, OR
  • Failing to go into remission from original diagnosis after 2 previous induction attempts.
  • Hematopoietic Stem Cell Transplant: Patients who have experienced their relapse after a HSCT are eligible, provided they have no evidence of Graft-versus-Host Disease (GVHD) and are at least 60 days post-transplant at the time of enrollment.
  • Prior anthracycline exposure: Patients must have less than 400 mg/m2 lifetime exposure of anthracycline chemotherapy. (See Appendix II for calculation worksheet)
  • Hematopoietic grow factors: It must have been at least 7 days since the completion of therapy with GCSF or other growth factors at the time of enrollment. It must have been at least 14 days since the completion of therapy with pegfilgrastim (Neulasta®).
  • Biologic (anti-neoplastic) therapy: It must be at least 7 days after last does of biologic agent. For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval must be discussed with the study chair
  • Monoclonal antibodies: At least 3 half-lives of the antibody must have elapsed after the last dose of monoclonal antibody. (ie. Rituximab=66 days, Epratuzumab=69 days)
  • Immunotherapy: At least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines.

Renal and Hepatic Function

  • Patient's serum creatinine must be ≤ 1.5 x institutional upper limit of normal (ULN) according to age. If the serum creatinine is greater than 1.5 times normal, the patient must have a calculated creatinine clearance or radioisotope GRF ≥ 70mL/min/1.73m2.
  • Patient's ALT and AST must be < 5 x institutional upper limit of norm ULN. The hepatic requirements are waived for patients with known or suspected liver involvement who would otherwise be eligible after consultation with the Study Chair or Vice Chair.
  • Patient's total bilirubin must be ≤ 1.5 x ULN. The hepatic requirements are waived for patients with known or suspected liver involvement who would otherwise be eligible.

Cardiac Function:

  • Patient must have a shortening fraction ≥ 27% by Echo or an ejection fraction ≥ 50% by MUGA.

Reproductive Function

  • Female patients of childbearing potential must have a negative urine or serum pregnancy test confirmed prior to enrollment.
  • Female patients with infants must agree not to breastfeed their infants while on this study.
  • Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study.

Exclusion Criteria:

  • Patients will be excluded if they are unable to swallow capsules.
  • Patients will be excluded if they are receiving Valproic Acid (VPA) therapy.
  • Patients will be excluded if they have a known allergy to any of the drugs used in the study.
  • Patients will be excluded if they have a systemic fungal, bacterial, viral or other infection that is exhibiting ongoing signs/symptoms related to the infection without improvement despite appropriate antibiotics or other treatment.
  • Patients will be excluded if there is a plan to administer non-protocol chemotherapy, radiation therapy, or immunotherapy during the study period.
  • Patients will be excluded if they have significant concurrent disease, illness, psychiatric disorder or social issue that would compromise patient safety or compliance with the protocol treatment or procedures, interfere with consent, study participation, follow up, or interpretation of study results.
  • Patients will be excluded if they have had any positive fungal culture in the last 30 days prior to enrollment.
Both
1 Year to 21 Years
No
Contact: Jeannette van der Giessen 323-361-8725 jvandergiessen@chla.usc.edu
Contact: Elena Eckroth 323-361-5429 eeckroth@chla.usc.edu
Canada,   United States,   Australia
 
NCT01483690
T2009-003
Yes
Therapeutic Advances in Childhood Leukemia Consortium
Therapeutic Advances in Childhood Leukemia Consortium
Not Provided
Study Chair: Michael Burke, MD University of Minnesota Children's Hospital
Therapeutic Advances in Childhood Leukemia Consortium
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP